報價延遲最少15分鐘:2024/12/23 22:24 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.92 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.61/--
|
|
企業價值
7.77M
|
| 資產負債 |
|
每股賬面淨值
1.99
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
8.56K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/23 22:24 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developinga proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. |